Compare Rocket Lab USA Inc (RKLB) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rocket Lab USA Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Rocket Lab USA Inc trades at $67.42 (market cap $43.74B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.71 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rocket Lab USA Inc for 29 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| RKLB | TAK | |
|---|---|---|
Market Cap | $43.74B | $58.74B |
Volume | 22,892,581 | 3,110,994 |
Sector | Industrials | Health |
52-Week High | $150.23 | $19.05 |
52-Week Low | $39.48 | $13.23 |
Typical Hold Time | 29 Days | 0 Days |
Enterprise Value | $41.57B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rocket Lab (RKLB) trades at $67.47, down 6.19% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of -$198.21M in 2025, though revenue grew to $601.80M. Recent news highlights a record 20-launch deal with Synspective, expanding the backlog past 100 missions, providing a positive catalyst amid ongoing losses and high valuation multiples.
The outlook remains speculative; strong analyst consensus (76% buy ratings) and a $107 price target suggest long-term growth potential from launch demand, but profitability challenges, cash burn, and competitive pressure from SpaceX pose significant risks. Investment hinges on execution toward Neutron rocket commercialization and path to sustained profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
